Top

Published in:

01-07-2015 | Editorial

For a Step Change to Curb the Obesity Epidemic

Authors: Christian Frois, Pierre-Yves Cremieux

Published in: PharmacoEconomics | Issue 7/2015

Excerpt

Rising obesity levels worldwide have been of increasing public concern since the late 1990s and are now responsible for over one-quarter of total healthcare expenditures in the USA [1]. This special issue of PharmacoEconomics examines a particularly challenging set of issues, with an economic focus: why is the obesity epidemic and its unique burden still growing uncontrolled? how have past efforts to curb it fared? and what other actions are needed to succeed in controlling the epidemic? Contributors to the issue cover a broad range of topics, experience, and perspectives related to obesity. Taken together these articles give some sense of the urgency, challenges, and opportunity for action in this field. …

Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics. 2014. doi:10.1007/s40273-014-0230-2.PubMed

Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2014. doi:10.1007/s40273-014-0243-x.PubMed

Corica F, Bianchi G, Corsonello A, Mazzella N, Lattanzio F, Marchesini G. Obesity in the context of aging: quality of life considerations. Pharmacoeconomics. 2014. doi:10.1007/s40273-014-0237-8.PubMed

Li Q, Blume SW, Huang JC, Hammer M, Graf TR. The economic burden of obesity by glycemic stage in the United States. Pharmacoeconomics. 2015. doi:10.1007/s40273-014-0248-5.PubMed

Allen L, Thorpe K, Joski P. Medicare spending for obesity and selected obesity-related chronic conditions, 1987–2011. Pharmacoeconomics. 2015. doi:10.1007/s40273-015-0284-9.

Gaudette É, Goldman DP, Messali A, Sood N. Do statins reduce the health and health care costs of obesity? Pharmacoeconomics. 2015. doi:10.1007/s40273-014-0234-y.PubMed

Centers for Disease Control and Prevention. Obesity and overweight for professionals: data and statistics—adult obesity. Centers for Disease Control and Prevention. 2014. http://www.cdc.gov/obesity/data/adult.html. Accessed 3 Feb 2015.

Centers for Disease Control and Prevention. Obesity and overweight for professionals: childhood obesity facts—prevalence of childhood obesity in the United States, 2011–2012. Centers for Disease Control and Prevention. 2014. http://www.cdc.gov/obesity/data/childhood.html. Accessed 3 Feb 2015.

Kockaya G. What are the top most costly diseases for USA? The alignment of burden of illness with prevention and screening expenditures. Health (Irvine Calif). 2010;02(10):1174–8.

10.

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.PubMedCrossRef

11.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–46.PubMedCentralCrossRef

12.

Kirkham HS, Clark BL, Bolas CA, Lewis GH, Jackson AS, Fisher D, et al. Which modifiable health risks are associated with changes in productivity costs? Popul Health Manag. 2015;18(1):30–8.PubMedCrossRef

13.

Gates DM, Succop P, Brehm BJ, Gillespie GL, Sommers BD. Obesity and presenteeism: the impact of body mass index on workplace productivity. J Occup Environ Med. 2008;50(1):39–45.PubMedCrossRef

14.

Ricci JA, Chee E. Lost productive time associated with excess weight in the U.S. workforce. J Occup Environ Med. 2005;47(12):1227–34.PubMedCrossRef

15.

United Health Foundation, the American Public Health Association, Partnership for Prevention. The future costs of obesity: national and state estimates of the impact of obesity on direct health care expenses. United Health Foundation. 2009. Available from: http://www.nccor.org/downloads/CostofObesityReport-FINAL.pdf. Accessed 26 March 2015.

16.

Stamler J. Epidemic obesity in the United States. Arch Intern Med. 1993;153(9):1040–4.PubMedCrossRef

17.

Dobbs R, Sawers C, Thompson F, Manyika J, Woetzel J, Child P, et al. Overcoming obesity: an initial economic analysis. McKinsey Global Institute. 2014. http://www.mckinsey.com/~/media/McKinsey/dotcom/Insights/EconomicStudies/Howtheworldcouldbetterfightobesity/MGIObesity_Fullreport_November2014.ashx. Accessed 3 Dec 2014.

18.

Cecchini M, Sassi F. Preventing obesity in the US: impact on health service utilization and costs. Pharmacoeconomics. 2015. doi:10.1007/s40273-015-0301-z.PubMed

19.

Chawla AS, Hsiao CCW, Romney MC, Cohen R, Rubino F, Schauer P, et al. Gap between evidence and patient access: policy implications for bariatric and metabolic surgery in treatment of obesity and its complications. Pharmacoeconomics. 2015. doi:10.1007/s40273-015-0302-y.

20.

Baum C, Andino K, Wittbrodt E, Stewart S, Szymanski K, Turpin R. The challenges and opportunities associated with reimbursement for obesity pharmacotherapy in the United States. Pharmacoeconomics. 2015. doi:10.1007/s40273-015-0264-0.

21.

Chawla A, Carls G, Deng E, Tuttle E. The expected net present value of developing weight management drugs in the context of drug safety litigation. Pharmacoeconomics. 2015. doi:10.1007/s40273-015-0300-0.

22.

Hawkes C, Ahern AL, Jebb SA. A stakeholder analysis of the perceived outcomes of developing and implementing England’s obesity strategy 2008–2011. BMC Public Health. 2014;14:441.PubMedCentralPubMedCrossRef

23.

Gill TP. Key issues in the prevention of obesity. Br Med Bull. 1997;53(2):359–88.PubMedCrossRef

24.

Heymann EP, Goldsmith D. Best approaches in the battle against Globesity? Learning lessons from our experience tackling HIV-AIDS and tobacco smoking. JRSM Short Rep. 2012;3(7):45.PubMedCentralPubMedCrossRef

25.

Eyal N. Denial of treatment to obese patients—the wrong policy on personal responsibility for health. Int J Heal policy Manag. 2013;1(2):107–10.CrossRef

26.

Finkelstein EA, Kruger E, Karnawat S. Cost-effectiveness analysis of Qsymia for weight loss. Pharmacoeconomics. 2014. doi:10.1007/s40273-014-0182-6.PubMed

27.

Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.PubMedCentralPubMedCrossRef

28.

Pasanisi F, Contaldo F, de Simone G, Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis. 2001;11(6):401–6.PubMed

29.

Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane database Syst Rev. 2014;8:CD003641.PubMed

30.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2009;13(41):1–190, 215–357, iii–iv.

31.

Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg. 2007;17(9):1248–56.PubMedCrossRef

32.

Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–55.PubMedCentralPubMedCrossRef

33.

Deitel M. Bariatric surgery is a cost-saving for the healthcare system. Obes Surg. 2005;15(3):301–3.PubMedCrossRef

34.

Borisenko O, Adam D, Funch-Jensen P, Ahmed AR, Zhang R, Colpan Z, et al. Bariatric surgery can lead to net cost savings to health care systems: results from a comprehensive European decision analytic model. Obes Surg. 2015. doi:10.1007/s11695-014-1567-5.PubMedCentral

35.

Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg. 2005;200(2):270–8.PubMedCrossRef

36.

Karim MA, Clifton E, Ahmed J, Mackay GW, Ali A. Economic evaluation of bariatric surgery to combat morbid obesity: a study from the West of Scotland. Asian J Endosc Surg. 2013;6(3):197–202.PubMedCrossRef

37.

Sánchez-Santos R, Sabench Pereferrer F, Estévez Fernandez S, del Castillo Dejardin D, Vilarrasa N, Frutos Bernal D, et al. Is the morbid obesity surgery profitable in times of crisis? A cost-benefit analysis of bariatric surgery. Cirugía española. 2013;91(8):476–84.PubMedCrossRef

38.

Terranova L, Busetto L, Vestri A, Zappa MA. Bariatric surgery: cost-effectiveness and budget impact. Obes Surg. 2012;22(4):646–53.PubMedCrossRef

39.

Chang S-H, Stoll CRT, Colditz GA. Cost-effectiveness of bariatric surgery: should it be universally available? Maturitas. 2011;69(3):230–8.PubMedCrossRef

40.

Finkelstein EA, Allaire BT, Burgess SM, Hale BC. Financial implications of coverage for laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2011;7(3):295–303.PubMedCrossRef

41.

Crémieux P-Y, Ghosh A, Yang HE, Buessing M, Buchwald H, Shikora SA. Return on investment for bariatric surgery. Am J Manag Care. 2008;14(11):e5–6.PubMed

42.

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14.PubMedCrossRef

43.

Arena Pharmaceuticals GmbH. BELVIQ (lorcaserin hydrochloride) tablets. In: Fda.gov Product Label. U.S. Food and Drug Administration. 2012. p. 1–28. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Accessed 3 May 2015.

44.

Takeda Pharmaceuticals America Inc. CONTRAVE (naltrexone HCl and bupropion HCl) Extended- Release Tablets. In: Fda.gov Product Label. U.S. Food and Drug Administration. 2014. p. 1–47. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed 3 May 2015.

45.

VIVUS Inc. QSYMIA (phentermine and topiramate extended—release) capsules. In: Fda.gov Product Label. U.S. Food and Drug Administration. 2014. p. 1–43. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022580s010s011s012lbl.pdf. Accessed 3 May 2015.

46.

Novo Nordisk. SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous use. In: Fda.gov Product Label. U.S. Food and Drug Administration. 2015. p. 1–31. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206321s001lbl.pdf. Accessed 3 May 2015.

47.

Cremieux P. Policy-makers’ view of obesity-related challenges around the world. Pharmacoeconomics. doi:10.1007/s40273-015-0290-y.

48.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Bariatric surgery for severe obesity: estimate of bariatric surgery numbers. The American Society for Metabolic and Bariatric Surgery (ASMBS). 2014. http://www.niddk.nih.gov/health-information/health-topics/weight-control/bariatric-surgery-severe-obesity/Pages/bariatric-surgery-for-severe-obesity.aspx. Accessed 8 April 2015.

49.

Finkelstein EA, Allaire BT, Globe D, Dixon JB. The business case for bariatric surgery revisited: a non-randomized case-control study. Folli F, editor. PLoS One. 2013;8(9):e75498.

50.

Hartman M, Martin AB, Lassman D, Catlin A. National health spending in 2013: growth slows, remains in step with the overall economy. Health Aff. 2015;34(1):150–60.

51.

Aetna. Aetna Promotes Personalized weight-loss options. (Press release). Aetna Inc. 2014. https://news.aetna.com/news-releases/aetna-promotes-personalized-weight-loss-options/. Accessed 4 May 2015.

52.

Aetna tests the weight-loss drug waters with new pilot and pharma collaboration. Drug Benefit News. 2014;15(2).

53.

Saadi E, White G. Rewarding innovation in drug development. Am Health Drug Benefits. 2014;7(7):373–4.PubMedCentralPubMed

54.

Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33–54.PubMedCentralPubMed

55.

Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. J Diabetes Sci Technol. 2008;2(5):913–8.PubMedCentralPubMedCrossRef

56.

Rodgers RJ, Tschöp MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621–6.PubMedCentralPubMedCrossRef

57.

Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for evaluating patient outcomes: a user’s guide. 3rd edn. Rockville: Agency for Healthcare Research and Quality (US); 2014.

58.

Greenwald P, Sondik EJ, Young JL. Emerging roles for cancer registries in cancer control. Yale J Biol Med. 1986;59(5):561–6.PubMedCentralPubMed

59.

Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a National Resource. Cancer Epidemiol Biomark Prev. 1999;8(12):1117–21.

60.

Cooperberg MR. Progress in management of low-risk prostate cancer: how registries may change the world. Eur Urol. 2015;67(1):51–2.PubMedCrossRef

Title: For a Step Change to Curb the Obesity Epidemic
Authors: Christian Frois
Pierre-Yves Cremieux
Publication date: 01-07-2015
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 7/2015
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-015-0303-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

For a Step Change to Curb the Obesity Epidemic

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2015

Policy Makers’ Views of Obesity-Related Challenges Around the World

The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation

Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications

Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status

Obesity in the Context of Aging: Quality of Life Considerations

Do Statins Reduce the Health and Health Care Costs of Obesity?